{
    "nct_id": "NCT02764762",
    "official_title": "An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk for Developing Complications",
    "inclusion_criteria": "1. Has an initial diagnosis of CD established within 24 months prior to screening with involvement of the ileum and/or colon that can be assessed by ileocolonoscopy.\n2. Has moderate to severely active CD during Screening defined by a centrally assessed simple endoscopic score for Crohn disease (SES-CD) score >=7 (or >=4 if isolated ileal disease).\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "Gastrointestinal (GI) Exclusion Criteria\n\n1. Has a diagnosis of ulcerative colitis (UC) or indeterminate colitis.\n2. Has clinical evidence of a current abdominal abscess or a history of prior abdominal abscess.\n3. Has a known perianal fistula with abscess. (The participant may have a perianal fistula without abscess.)\n4. Has a known fistula (other than perianal fistula).",
    "miscellaneous_criteria": ""
}